{"product_id":"athe-vrio-analysis","title":"Alterity Therapeutics Limited (ATHE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Alterity Therapeutics Limited (ATHE)'s market position starts here: this concise VRIO Analysis cuts straight to the core, evaluating every key resource against the pillars of Value, Rarity, Inimitability, and Organization. Discover immediately whether the firm possesses truly sustainable competitive advantages or if its strengths are easily replicable. Read on to grasp the distilled summary of Alterity Therapeutics Limited (ATHE)'s strategic reality.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Lead Asset Clinical Data (ATH434 in MSA)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core value proposition for Alterity Therapeutics Limited, which hinges entirely on the clinical success of ATH434 in Multiple System Atrophy (MSA). Honestly, for a clinical-stage biotech, the asset is the company, so this analysis is critical for any decision-making right now.\u003c\/p\u003e\n\n\u003cp\u003eThe immediate takeaway is that the data package for ATH434 is strong enough to warrant continued, aggressive development, especially given the FDA's Fast Track designation granted in May 2025. If Phase 3 confirms these signals, Alterity Therapeutics has a potential first-in-class, disease-modifying therapy on its hands.\u003c\/p\u003e\n\n\u003ch3\u003eATH434 VRIO Assessment\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how ATH434 stacks up against the VRIO framework:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment for ATH434 in MSA\u003c\/th\u003e\n    \u003cth\u003eImplication\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eDemonstrates clinically meaningful efficacy. The 75 mg dose showed a −2.8 UMSARS I points effect at 52 weeks in a key analysis, translating to a 35% relative treatment effect versus placebo.\u003c\/td\u003e\n    \u003ctd\u003eResource is Valuable.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003ePositive, robust Phase 2 data for a therapy that claims to be disease-modifying in MSA is exceptionally rare due to the high unmet need and disease complexity.\u003c\/td\u003e\n    \u003ctd\u003eResource is Rare.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eInimitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eThe specific clinical trial results, patient response data, and the mechanism of action (iron chaperone) are proprietary and cannot be directly copied.\u003c\/td\u003e\n    \u003ctd\u003eResource is Costly to Imitate.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eThe company is clearly organized to exploit this by planning engagement with the FDA based on the positive data, including securing Fast Track designation in May 2025.\u003c\/td\u003e\n    \u003ctd\u003eOrganization is Optimized.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e, provided subsequent Phase 3 trials confirm these signals and lead to market exclusivity.\u003c\/td\u003e\n    \u003ctd\u003ePotential for Long-Term Success.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue: Clinical Meaningfulness\u003c\/h3\u003e\n\u003cp\u003eValue comes from efficacy that matters to regulators and patients. The modified Unified MSA Rating Scale Part I (UMSARS I) is the key clinical endpoint for regulatory approval. The latest analysis of the ATH434-201 trial, which accounted for baseline orthostatic hypotension (OH), showed the 75 mg dose achieved a −2.8 UMSARS I points change at 52 weeks. To be fair, the initial analysis showed a 29% slowing at 52 weeks for this dose. Plus, the open-label ATH434-202 trial in more advanced patients showed comparable efficacy, which really helps build confidence in the drug's profile.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is that the 50 mg dose showed a 48% slowing of progression (p=0.03) in the initial analysis. You need to watch which endpoint the FDA prioritizes for the Phase 3 design.\u003c\/p\u003e\n\n\u003ch3\u003eRarity and Imitability: The Data Moat\u003c\/h3\u003e\n\u003cp\u003eFinding positive Phase 2 data for a disease-modifying therapy in MSA is incredibly rare; frankly, there are no approved treatments that slow progression right now. That lack of competition makes the data inherently rare. The specific patient data sets and the intellectual property around ATH434 - its specific chemical structure as an iron chaperone - mean direct imitation is impossible. You can’t just replicate a clinical trial’s outcome overnight, especially with a novel mechanism targeting iron redistribution.\u003c\/p\u003e\n\u003cp\u003eThe company’s focus is clear:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTargeting $\\alpha$-synuclein pathology.\u003c\/li\u003e\n  \u003cli\u003eRestoring normal iron balance in the brain.\u003c\/li\u003e\n  \u003cli\u003eDemonstrating target engagement via MRI biomarkers showing reduced iron accumulation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization: Capitalizing on Momentum\u003c\/h3\u003e\n\u003cp\u003eAlterity Therapeutics is organized to push this forward. They secured U.S. FDA Fast Track designation in May 2025, which is a huge organizational win for accelerating development. Their cash position as of September 30, 2025, was A\\$54.56M, bolstered by a A\\$20M strategic placement during the quarter. This funding, combined with a market cap of \\$77.9M as of October 2025, suggests they have the runway to plan for Phase 3 engagement with the FDA, as they stated they look forward to doing. They are definitely putting their resources behind the data.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: US FDA Fast Track Designation for ATH434\n\u003c\/h2\u003e\n\u003cp\u003e\nThe US FDA Fast Track Designation for ATH434 in Multiple System Atrophy (MSA) is a significant regulatory milestone.\n\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003e\nThis designation is intended to accelerate the development and review of ATH434, which addresses MSA, a disease with no approved therapy. The potential benefit is supported by clinical data showing efficacy in slowing disease progression.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEligibility for Accelerated Approval.\u003c\/li\u003e\n\u003cli\u003eOpportunity for more frequent interaction with the FDA on advancement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial\/Dose\u003c\/th\u003e\n\u003cth\u003eEndpoint (UMSARS I)\u003c\/th\u003e\n\u003cth\u003eResult vs. Placebo\/Historical\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434-201 (50 mg, Week 52)\u003c\/td\u003e\n\u003ctd\u003eSlowing of Clinical Progression\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48%\u003c\/strong\u003e slowing (p=0.03)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434-201 (75 mg, Week 26)\u003c\/td\u003e\n\u003ctd\u003eSlowing of Clinical Progression\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e62%\u003c\/strong\u003e slowing (p=0.05)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434-202 (12 months)\u003c\/td\u003e\n\u003ctd\u003eUMSARS I Progression\u003c\/td\u003e\n\u003ctd\u003eReduced by approximately \u003cstrong\u003ehalf\u003c\/strong\u003e vs. historical controls\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\nThe designation, granted in May 2025, for a novel MSA therapy is a valuable regulatory achievement, received alongside an existing Orphan Drug Designation.\n\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\nA designation already granted by the FDA to Alterity Therapeutics for ATH434 cannot be imitated by competitors for their own assets.\n\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\nThe company is leveraging this status to guide its clinical and regulatory strategy. Proceeds from a recent capital raise of \u003cstrong\u003eA$20.0 million\u003c\/strong\u003e are allocated to fund clinical and regulatory engagement with the US FDA for future development. The cash balance as of June 30, 2025, was \u003cstrong\u003eA$40.66M\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\nThe advantage is currently temporary, tied to the specific drug indication, but highly valuable given the potential market size. An independent commercial assessment indicated a potential worldwide peak sales opportunity of approximately \u003cstrong\u003eUSD $2.4 billion\u003c\/strong\u003e in MSA for ATH434.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Strong Balance Sheet (Post-Placement)\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe balance sheet strength is evidenced by the cash position at the end of Q1 FY26, reported as \u003cstrong\u003eA$54.56M\u003c\/strong\u003e as of 30 September 2025. This position was significantly bolstered by a strategic placement completed during the quarter, which raised gross proceeds of \u003cstrong\u003eA$20.0 million\u003c\/strong\u003e. This capital infusion provides a substantial operational buffer, intended to advance clinical and regulatory strategy for ATH434 with the US FDA and support general working capital needs.\u003c\/p\u003e\n\n\u003cp\u003eKey financial and operational metrics supporting this assessment include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Value\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$54.56M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e30 September 2025 (End Q1 FY26)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlacement Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$20.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 FY26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Outflows\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$5.34M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 FY26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434 Potential Peak Sales (MSA)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD $2.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndependent Commercial Assessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434 Efficacy (75mg Dose, 52 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35%\u003c\/strong\u003e relative treatment effect\u003c\/td\u003e\n\u003ctd\u003eModified USMARS I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA cash balance exceeding \u003cstrong\u003eA$54 million\u003c\/strong\u003e is considered relatively strong for a clinical-stage biotechnology company of Alterity's market profile at this juncture in its development cycle, providing a distinct advantage in funding near-term milestones.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eWhile capital raising is a standard activity for clinical-stage firms, the successful execution of the \u003cstrong\u003eA$20.0 million\u003c\/strong\u003e placement was secured based on the strength of the existing data package for ATH434, including Phase 2 trial results, which provided the necessary investor confidence.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe placement was anchored by a high-quality international healthcare-focused fund.\u003c\/li\u003e\n\u003cli\u003eThe pricing was at a \u003cstrong\u003e7.7%\u003c\/strong\u003e discount to the last ASX closing price prior to the trading halt.\u003c\/li\u003e\n\u003cli\u003eThe placement was conducted at \u003cstrong\u003eA$0.012\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eManagement demonstrated efficiency in structuring the capital raise to preserve the existing capital structure and shareholder equity value.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003eA$20.0 million\u003c\/strong\u003e placement involved \u003cstrong\u003eno options\u003c\/strong\u003e being issued as part of the transaction.\u003c\/li\u003e\n\u003cli\u003eThe new shares issued rank equally with existing fully paid ordinary shares.\u003c\/li\u003e\n\u003cli\u003eThe execution was designed to strengthen the institutional register while positioning the company for strategic partnerships.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe current financial buffer, derived from the \u003cstrong\u003eA$54.56M\u003c\/strong\u003e cash position, offers a significant, albeit temporary, operational advantage by allowing focused advancement of the ATH434 program towards an End-of-Phase 2 meeting with the FDA, which is expected in mid-year 2026.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Experienced Executive Leadership\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eExperienced Executive Leadership\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eDescription \u0026amp; Data Points\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCEO Dr. David Stamler has over 30 years in the pharmaceuticals industry, including guiding three CNS drug approvals with the US FDA for drugs in the neurological space, which is invaluable for navigating late-stage development and regulatory pathways, such as the recent FDA Fast Track Designation for ATH434.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA CEO with a proven track record of three successful CNS drug approvals by the US FDA is rare in a clinical-stage company with 9.00 employees.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompetitors cannot instantly hire or replicate this specific, successful executive experience, which has guided the lead asset, ATH434, to Phase 3 planning.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe recent appointment of Dr. Stamler to Managing Director and CEO effective November 21, 2025, shows the board is organized around this leadership for the next phase, following a recent capital raise of $40 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained, as long as this leadership remains in place to leverage experience through the critical end of Phase 2 meeting planned for mid-year (relative to Nov 2025).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe executive leadership's experience is supported by the company's financial position, with Cash, cash equivalents and short term investments reported at $40.66M as of the latest balance sheet data, following a recent $40 million capital raise.\u003c\/p\u003e\n\u003cp\u003eThe organizational structure and leadership focus are further evidenced by the progression of the lead asset:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eATH434 has received Orphan Drug Designation from the U.S. FDA and the European Commission for the treatment of Multiple System Atrophy (MSA).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company's Trailing Twelve Months (TTM) Revenue was 446.29k AUD, with a TTM Net Income of -12.15m AUD.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eDr. Stamler's tenure has seen the company advance ATH434 through two Phase 2 trials in MSA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Broad Drug Discovery Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eBroad Drug Discovery Platform\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This platform generates patentable chemical compounds to treat the underlying pathology of neurological diseases, offering future pipeline optionality beyond ATH434.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform is central to the next generation drug development portfolio for neurogenerative diseases.\u003c\/li\u003e\n\u003cli\u003eThe lead asset, ATH434, has an estimated peak sales potential of \u003cstrong\u003eUS$725M\u003c\/strong\u003e in Multiple System Atrophy (MSA).\u003c\/li\u003e\n\u003cli\u003eThe platform's output is designed to treat indications including Alzheimer's disease, Huntington disease, Parkinsonian movement disorders, and selected cancers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having a functional platform that consistently yields patentable leads is rarer than having a single successful drug candidate.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Output Metric\u003c\/td\u003e\n\u003ctd\u003eQuantity\/Detail\u003c\/td\u003e\n\u003ctd\u003eSource Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovel Pharmaceutical Compositions (US Patent)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 150\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovel Pharmaceutical Compositions (EU Patent)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 150\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434 Phase 2 Trial Enrollment (Early-Stage MSA)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e77\u003c\/strong\u003e adults enrolled in ATH434-201 trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATH434 Phase 2 Trial Arms (ATH434-201)\u003c\/td\u003e\n\u003ctd\u003eThree arms: Placebo, \u003cstrong\u003e50 mg\u003c\/strong\u003e (n=25), \u003cstrong\u003e75 mg\u003c\/strong\u003e (n=24).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific chemical libraries and screening processes are proprietary and hard to copy quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eA US patent covers next generation compounds based on in-house discovery research.\u003c\/li\u003e\n\u003cli\u003eA European composition of matter patent secures broad protection over a new class of iron chaperone drug candidates.\u003c\/li\u003e\n\u003cli\u003eThe European patent confers 20 years of exclusivity over the claimed compounds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company continues to invest in this platform, showing commitment to its long-term value.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eYear Ended June 30, 2022 (AUD)\u003c\/td\u003e\n\u003ctd\u003eYear Ended June 30, 2021 (AUD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Employee)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,517,516\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,169,420\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Other)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,228,260\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,114,428\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14,745,776\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,283,848\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eThe company secured \u003cstrong\u003e$20 million\u003c\/strong\u003e in new funding in 2025 to accelerate development, funding non-clinical studies, chemical manufacturing, and clinical\/regulatory engagement.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses primarily consist of contracted research and development activities conducted by third parties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if the platform continues to generate novel, patentable assets.\u003c\/p\u003e\n\u003cp\u003eThe platform's output is protected by patents providing exclusivity periods up to 20 years.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Intellectual Property Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntellectual Property Portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe portfolio protects ATH434 and other potential candidates, securing the exclusive right to commercialize the therapeutic approach. The potential market opportunity for ATH434 in Multiple System Atrophy (MSA) is estimated by an independent commercial assessment to be approximately \u003cstrong\u003eUSD $2.4 billion\u003c\/strong\u003e in peak sales.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eWhile all biotechs have IP, Alterity Therapeutics' IP covers a novel mechanism targeting protein aggregation and iron balance. ATH434 is described as an iron chaperone that targets the labile, or reactive, form of iron, a feature not observed in another investigated iron binding agent approved for iron overload.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eATH434 is designed to inhibit $\\alpha$-synuclein aggregation by restoring normal iron balance in the brain.\u003c\/li\u003e\n\u003cli\u003eATH434 successfully completed Phase 1 studies, achieving brain levels comparable to efficacious levels in animal models of MSA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003ePatents provide legal barriers to entry, making direct imitation illegal for the patent's life. The global patent portfolio includes several composition of matter patents:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent\/Application Type\u003c\/th\u003e\n\u003cth\u003eCoverage Scope\u003c\/th\u003e\n\u003cth\u003eExclusivity Term\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent No. 10,941,143\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e150\u003c\/strong\u003e novel compounds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Patent No. 3938364\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e150\u003c\/strong\u003e novel pharmaceutical compositions\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent Application No. 17\/239,375 (Notice of Allowance)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e80\u003c\/strong\u003e novel compounds\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e20 years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe acyl hydrazone (AH) patent (No. 11,603,364) covers over \u003cstrong\u003e100\u003c\/strong\u003e novel compounds.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eManagement explicitly states they continue to strengthen this portfolio as they advance programs. The company's operations are supported by financial mechanisms that aid R\u0026amp;D:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFor the year ended June 30, 2024, the company recorded \u003cstrong\u003eA$4.0 million\u003c\/strong\u003e in other income related to the Research and Development Tax Incentive Scheme.\u003c\/li\u003e\n\u003cli\u003eThe company's Phase 2 clinical trial (ATH434-201) enrolled \u003cstrong\u003e77\u003c\/strong\u003e adults with early-stage MSA.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, the cash balance was reported as \u003cstrong\u003eA$54.56M\u003c\/strong\u003e, following a strategic placement that raised \u003cstrong\u003eA$20M\u003c\/strong\u003e in gross proceeds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained, as long as key patents remain in force. The US FDA has granted \u003cstrong\u003eFast Track designation\u003c\/strong\u003e for ATH434 for the treatment of Multiple System Atrophy.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Orphan Drug Designation Status (MSA)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOrphan Drug Designation Status (MSA)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe designation for ATH434 in the U.S. and EU provides significant commercial levers, including market exclusivity post-approval, which is a major commercial lever. An independent commercial assessment indicates a potential worldwide peak sales opportunity in MSA for ATH434 of approximately \u003cstrong\u003eUSD $2.4 billion\u003c\/strong\u003e, if approved.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003eMarket Exclusivity Period\u003c\/th\u003e\n\u003cth\u003eIncentives\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. (FDA)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTax credits for qualified clinical testing, reduced fees, access to EU-funded research grants (Note: Tax credits\/grants are US\/EU specific incentives).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU (European Commission)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProtocol assistance, fee reductions, access to EU-funded research grants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eATH434 has been granted Orphan Drug designation by the U.S. FDA and the European Commission for the treatment of MSA. MSA is a disease with no approved therapy.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis is a regulatory status granted by agencies; competitors cannot imitate a status already awarded to Alterity Therapeutics.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company has clearly prioritized MSA as its first indication to maximize the benefit of this status, evidenced by ongoing clinical trials:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe ATH434-201 Phase 2 trial enrolled approximately \u003cstrong\u003e77\u003c\/strong\u003e adults with early-stage MSA.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe ATH434-202 Phase 2 open-label trial treated \u003cstrong\u003eTen (10)\u003c\/strong\u003e participants with advanced MSA with ATH434 \u003cstrong\u003e75 mg\u003c\/strong\u003e twice daily for \u003cstrong\u003e12 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe cash balance on \u003cstrong\u003e30 September 2025\u003c\/strong\u003e was \u003cstrong\u003eA$54.56M\u003c\/strong\u003e, with operating cash outflows for the quarter of \u003cstrong\u003eA$5.34M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary, as it is tied to the specific drug (ATH434) and indication (MSA), but it de-risks commercialization through exclusivity periods of \u003cstrong\u003eseven years\u003c\/strong\u003e (U.S.) and \u003cstrong\u003eten years\u003c\/strong\u003e (EU) post-approval.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: Biomarker Validation Data\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eData showing target engagement, like stable iron levels and brain volume preservation, provides objective proof that ATH434 is hitting its intended biological target in patients.\u003c\/p\u003e\n\u003cp\u003eThe 50 mg dose reduced iron accumulation in the substantia nigra, putamen, and globus pallidus, with reduced accumulation in the putamen being statistically significant at 26 weeks (P=0.025) in the ATH434-201 trial. Trends in preservation of brain volume were observed in both the 50 mg and 75 mg groups relative to placebo. In the open-label ATH434-202 trial, clinical responders showed stable levels of NFL, a marker of axonal injury, over 12 months.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eBiomarker\/Measure\u003c\/th\u003e\n\u003cth\u003eTrial\/Dose\u003c\/th\u003e\n\u003cth\u003eResult\/Comparison\u003c\/th\u003e\n\u003cth\u003eStatistical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIron Accumulation (Putamen)\u003c\/td\u003e\n\u003ctd\u003eATH434-201 (50 mg) at 26 weeks\u003c\/td\u003e\n\u003ctd\u003eReduced\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eP=0.025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIron Accumulation (Globus Pallidus)\u003c\/td\u003e\n\u003ctd\u003eATH434-201 (50 mg) at 52 weeks\u003c\/td\u003e\n\u003ctd\u003eReduced (Trend)\u003c\/td\u003e\n\u003ctd\u003eApproached significance (P=0.08)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrain Volume (MSA-AI)\u003c\/td\u003e\n\u003ctd\u003eATH434 (50 mg \u0026amp; 75 mg) vs. Placebo\u003c\/td\u003e\n\u003ctd\u003eTrends in preservation\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUMSARS Part I Slowing\u003c\/td\u003e\n\u003ctd\u003eATH434-201 (50 mg) at Week 52\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48%\u003c\/strong\u003e slowing vs. placebo\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ep=0.03\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStable Neurological Symptoms\u003c\/td\u003e\n\u003ctd\u003eATH434-202 (Open-Label) over 12 months\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30%\u003c\/strong\u003e of participants\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eShowing clinical efficacy and corresponding biomarker changes in a neurodegenerative trial is a high bar and relatively rare.\u003c\/p\u003e\n\u003cp\u003eThe ATH434-201 trial enrolled 77 adults. Imaging biomarkers utilized in the ATH434-201 trial presented supportive features of MSA in 96.1% of the 77 enrolled subjects, compared to 78.9% for $\\alpha$-synuclein aggregation profiles in cerebrospinal fluid (CSF) alone (60 of 76). ATH434 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation by the FDA and the European Commission for MSA treatment.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe specific biomarker data generated from their trials is proprietary.\u003c\/p\u003e\n\u003cp\u003eThe company has a cash balance on 30 June 2025 of A$40.66M. The company secured $20 million in new funding in September 2025. The market capitalization as of 14-Oct-2025 was $77.9M with 10.9B shares.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe company actively presents this data at scientific congresses, showing they use it to build credibility.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eData from ATH434-201 presented at the 150th Annual Meeting of the American Neurological Association (ANA) in September 2025.\u003c\/li\u003e\n\u003cli\u003eData featured at the 2025 International Congress of Parkinson's Disease and Movement Disorders (MDS).\u003c\/li\u003e\n\u003cli\u003eThe company's operations are reported in one segment: research and development into Parkinsonian and related disorders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, as this data forms a strong foundation for regulatory filings.\u003c\/p\u003e\n\u003cp\u003eThe ATH434-201 trial demonstrated 29% slowing of clinical progression at the 75 mg dose (p=0.2) at Week 52 compared with placebo. The 75 mg dose group showed a 62% slowing of progression (p=0.05) at Week 26.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAlterity Therapeutics Limited (ATHE) - VRIO Analysis: High-Value Market Potential Estimate\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e An independent commercial assessment estimates a \u003cstrong\u003eUSD $2.4B\u003c\/strong\u003e peak sales opportunity in MSA.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While estimates are common, a \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e figure for a rare disease market is a significant, attention-grabbing valuation anchor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The estimate itself is not imitable, but the underlying market need is real and accessible to others.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management uses this figure to frame the upside when discussing financing and strategic partnerships. The company raised \u003cstrong\u003eA$20M\u003c\/strong\u003e gross proceeds via a strategic placement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as this estimate is contingent on successful Phase 3 results and regulatory acceptance. Clinical data shows ATH434 75 mg resulted in \u003cstrong\u003e−2.8 UMSARS I points\u003c\/strong\u003e at 52 weeks, representing a \u003cstrong\u003e35%\u003c\/strong\u003e relative effect.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e 13-Week Cash Flow Projection Context (Based on Q1 FY26 Data)\u003c\/p\u003e\n\u003cp\u003eThe Q1 FY26 Appendix 4C reported a cash balance of \u003cstrong\u003eA$54.56M\u003c\/strong\u003e as of September 30, 2025, and operating cash outflows of \u003cstrong\u003eA$5.34M\u003c\/strong\u003e for the quarter. The recent capital raise was \u003cstrong\u003eA$20M\u003c\/strong\u003e gross. The projected weekly burn rate for the 13-week projection is derived from the quarterly outflow.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eUnit\u003c\/td\u003e\n\u003ctd\u003eSource\/Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarting Cash Balance (Pre-Raise\/Post-Raise Context)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$54.56M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAUD\u003c\/td\u003e\n\u003ctd\u003eCash balance as of 30 Sep 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital Raise Incorporated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$20M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAUD\u003c\/td\u003e\n\u003ctd\u003eGross proceeds from strategic placement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Operating Cash Outflow (Burn)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$5.34M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAUD\u003c\/td\u003e\n\u003ctd\u003eQ1 FY26 Operating Cash Outflows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Weekly Cash Outflow (Burn Rate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~A$410,769\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAUD\/Week\u003c\/td\u003e\n\u003ctd\u003eA$5.34M \/ 13 Weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Runway (Weeks, Pre-Raise Cash)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~132.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWeeks\u003c\/td\u003e\n\u003ctd\u003eA$54.56M \/ A$0.410769M per week\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue (Annualized Context)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.44 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAUD\u003c\/td\u003e\n\u003ctd\u003e2025 Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Net Loss (Annualized Context)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-12.15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAUD\u003c\/td\u003e\n\u003ctd\u003e2025 Losses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey Clinical\/Financial Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIndependent commercial assessment estimates \u003cstrong\u003eUSD $2.4B\u003c\/strong\u003e peak sales opportunity in MSA.\u003c\/li\u003e\n\u003cli\u003eATH434 75 mg efficacy signal at 52 weeks: \u003cstrong\u003e−2.8 UMSARS I points\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRelative treatment effect for 75 mg dose: \u003cstrong\u003e35%\u003c\/strong\u003e at 52 weeks.\u003c\/li\u003e\n\u003cli\u003eCash balance as of September 30, 2025: \u003cstrong\u003eA$54.56M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross proceeds raised in strategic placement: \u003cstrong\u003eA$20M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating cash outflow for Q1 FY26: \u003cstrong\u003eA$5.34M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrailing Twelve Months (TTM) Net Income: \u003cstrong\u003e-12.15m AUD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516117049493,"sku":"athe-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/athe-vrio-analysis.png?v=1740144624","url":"https:\/\/dcf-model.com\/fr\/products\/athe-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}